Fuller & Thaler Asset Management
ANIK icon

Fuller & Thaler Asset Management’s Anika Therapeutics ANIK Stock Holding History

Fuller & Thaler Asset Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-103,700
Closed -$4.27M – 672
2015
Q1 		$4.27M Sell
103,700
-300
-0.3% -$12.1K 0.14% 154
2014
Q4 		$4.24M Buy
104,000
+1,600
+2% +$62.5K 0.15% 151
2014
Q3 		$3.75M Hold
102,400
– – 0.16% 149
2014
Q2 		$4.74M Sell
102,400
-14,250
-12% -$634K 0.2% 137
2014
Q1 		$4.79M Sell
116,650
-13,600
-10% -$506K 0.23% 136
2013
Q4 		$4.97M Sell
130,250
-3,250
-2% -$100K 0.27% 133
2013
Q3 		$3.19M Buy
+133,500
New +$3M 0.19% 168

Other funds holding ANIK

TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
LCP
Lombardia Capital Partners Pasadena, California $110M AUM 13.11% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
AAM
AMI Asset Management Los Angeles, California $1.74B AUM 26.89% 1-Year Est. Return

Fuller & Thaler Asset Management's ANIK Position: Q2 2015 in Review

Fuller & Thaler Asset Management sold out of Anika Therapeutics (ANIK) in Q2 2015, closing a stake of 103,700 shares — an estimated $4.27M sold.

Fuller & Thaler Asset Management first reported a position in ANIK in Q3 2013 and held it in 7 quarters. The position peaked at $4.97M in Q4 2013. 136 funds tracked by Wall St. Rank hold ANIK as of Q2 2015.

  • Fuller & Thaler Asset Management reported no remaining Anika Therapeutics position as of Q2 2015 after selling out during the quarter.
  • Fuller & Thaler Asset Management sold 103,700 Anika Therapeutics shares in Q2 2015, an estimated $4.27M.
  • Fuller & Thaler Asset Management first reported a position in Anika Therapeutics in Q3 2013 and held it in 7 quarters.
  • Fuller & Thaler Asset Management's Anika Therapeutics position peaked at $4.97M in Q4 2013.
  • 136 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2015.

Based on Fuller & Thaler Asset Management's 13F filing for Q2 2015, filed 17 Aug 2015.